Pulse Biosciences Inc (NASDAQ:PLSE) Director Maky Zanganeh acquired 18,240 shares of the company’s stock in a transaction dated Monday, March 20th. The stock was acquired at an average price of $23.34 per share, with a total value of $425,721.60. Following the purchase, the director now owns 263,935 shares in the company, valued at approximately $6,160,242.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Pulse Biosciences Inc (NASDAQ:PLSE) traded down 5.96% during trading on Monday, hitting $23.03. 426,087 shares of the stock were exchanged. Pulse Biosciences Inc has a 1-year low of $4.03 and a 1-year high of $25.15. The company’s market cap is $306.62 million. The firm’s 50-day moving average is $13.18 and its 200 day moving average is $7.81.

Your IP Address:

Pulse Biosciences Company Profile

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

5 Day Chart for NASDAQ:PLSE

Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.